Related Experiment Video
Updated: Jun 22, 2026

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children
Zühre Kaya1, Daniel J Weiner, Deniz Yilmaz
1Pediatric Hematology, Gazi University Faculty of Medicine, Ankara, Turkey.
Insights
Pretransplant pulmonary function tests in pediatric allogeneic blood and marrow transplantation (BMT) predict early respiratory failure. Early pulmonary complications significantly worsen survival, highlighting the need for vigilant monitoring and management post-transplant.
Area of Science:
- Pediatric Hematology/Oncology
- Pulmonology
- Transplantation Medicine
Background:
- Pulmonary complications (PC) are a major challenge in allogeneic blood and marrow transplantation (BMT).
- Pretransplant pulmonary function tests (PFTs) predict outcomes in adults, but data in pediatric BMT recipients are limited.
- Understanding PFTs' role in pediatric BMT is crucial for improving patient outcomes.
Purpose of the Study:
- To analyze infectious and noninfectious pulmonary complications (PC) in pediatric allogeneic BMT (allo-BMT).
- To evaluate the prevalence and course of PFT abnormalities before and after pediatric allo-BMT.
- To correlate pretransplant PFT findings with risks of PC, respiratory failure, and mortality in pediatric allo-BMT patients.
Main Methods:
- Retrospective review of 110 pediatric patients undergoing allo-BMT from 1996-2006.
- Pulmonary function tests (PFTs) performed pre-BMT and at 3, 6, 12, and 24 months post-BMT for patients aged 6+.
- Analysis of early PCs (within 100 days) and correlation with PFTs, respiratory failure, mechanical ventilation, and survival.
Main Results:
- Reduced pretransplant forced expiratory volume in 1 second (FEV(1)) and forced vital capacity (FVC) significantly increased early respiratory failure risk (OR 5.1 and 8.5, respectively).
- Post-transplant, significant reductions in FEV(1), FVC, total lung capacity (TLC), and diffusing capacity (DLco) were observed at 3-6 months, with partial recovery by 12-24 months.
- Early PC was associated with a >4-fold reduction in 10-year survival probability and was a significant risk factor for death (HR 7.7).
Conclusions:
- Compromised pretransplant lung function in pediatric allo-BMT patients correlates with early respiratory failure risk.
- Lung function declines post-transplant, with partial recovery, but remains below pre-transplant levels.
- Early pulmonary complications significantly impact survival, underscoring the importance of PFTs and vigilant management in pediatric BMT.
Abstract:
Pulmonary complications (PC) remain a significant barrier to the success of allogeneic blood and marrow transplantation (BMT). Pretransplant pulmonary function tests (PFTs) have been correlated with risk of early respiratory failure and mortality in adult BMT recipients. There is limited data on their relationship to posttransplant outcomes in pediatric patients. We sought, in pediatric allo-BMT recipients (1) to analyze the spectrum of infectious and noninfectious PCs, (2) to evaluate the prevalence and course of PFT abnormalities before and after transplant, and (3) to correlate pretransplant PFT findings with patient outcomes, specifically risk of PC, respiratory failure, and death. We conducted a retrospective review of PC in all patients who underwent allo-BMT at Children's Hospital of Pittsburgh during 1996 to 2006. PFTs were performed in children 6 years and older pretransplant, 3, 6, 12, and 24 months after transplant. PCs occurring within 100 days of BMT were considered early. One hundred ten consecutive children who underwent allo-BMT were included (median age = 9.7 years; 67 males, 43 females). Seventy-five of 110 patients had 370 PFT studies performed; 62 of 73 patients >6 years of age (85%) underwent PFT studies pre-BMT. There was a significantly higher risk of early respiratory failure in patients with reduced pretransplant forced expiratory volume in 1 second (FEV(1)) (P = .0001, odds ratio [OR] 5.1) or forced vital capacity (FVC) (P = .0001, OR 8.5). Forty-three of 110 (39%) patients required mechanical ventilation, and in 30 episodes (70%), patients remained ventilator-dependent until time of death. Posttransplant, we observed statistically significant reductions in FEV(1), FVC, total lung capacity (TLC), and diffusing capacity of the lungs (DLco) at 3 months post-BMT and similar reductions at 6 months post-BMT except for DLco (not significant). Between 12 and 24 months, FEV(1), FVC, TLC, and DLco improved significantly from earlier declines post-BMT; however FEV(1) and FVC remained significantly below pretransplant values. At a median follow-up of 5.5 (1.6-11.6) years, 58 of 110 (53%) patients were surviving. The majority of the patients who died from transplant-related complications suffered from 1 or more PCs (31/32, 97%). Early PC was associated with over 4-fold reduction in probability of survival at 10 years (8/44, 18% with early PC versus 50/66, 76% without early PC). On multivariate analysis, risk of death was significantly associated with high-risk disease status (P = .015; hazard ratio [HR] = 2.5), unrelated donor (P = .03; HR = 2.1), early PC (P = .0001; HR = 7.7) and pathogen identification (P = .02; HR = 2.7). These results suggest that, in children undergoing allo-BMT (1) compromised pretransplant lung function is significantly correlated with risk of early respiratory failure but not of overall survival (OS), (2) reductions in lung volumes and diffusion capacity are common 3- to 6-month posttransplant with partial recovery by 12 to 24 months, (3) there is high mortality following mechanical ventilation, and (4) early PCs are associated with significantly worse OS.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant I: Introduction
